Background: Despite growing therapeutic relevance of ERBB2 amplifications in colorectal cancer (CRC), little is known about ERBB2/ERBB3 mutations. We aimed to characterize these subsets of CRC. Methods: We performed a retrospective analysis of 419 CRC patients from MD Anderson (MDACC) and 619 patients from the Nurses' Health Study (NHS)/Health Professionals Follow-Up Study (HPFS) with tissue sequencing, clinicopathologic, mutational, and consensus molecular subtype (CMS) profiles of ERBB2/ERBB3 mutant patients. A third cohort of 1623 CRC patients with ctDNA assays characterized the ctDNA profile of ERBB2 mutants. All statistical tests were two-sided. Results: ERBB2 mutations occurred in 4.1% (95% confidence interval [CI] = 2.4% to 6.4%), 5.8% (95% CI = 4.1% to 8.0%), and 5.1% (95% CI = 4.0% to 6.2%) of MDACC, NHS/HPFS, and ctDNA patients, respectively. ERBB3 mutations occurred in 5.7% (95% CI = 3.7% to 8.4%, 95% CI = 4.0% to 7.8%) of patients in both tissue cohorts. Age, stage, and tumor location were not associated with either mutation. Microsatellite instability (MSI) was associated with ERBB2 (odds ratio [OR] = 5.98, 95% CI = 2.47 to 14.49, P < .001; OR = 5.13, 95% CI = 2.38 to 11.05, P < .001) and ERBB3 mutations (OR = 3.48, 95% CI = 1.51 to 8.02, P = .002; OR = 3.40, 95% CI = 1.05 to 10.96, P = .03) in both tissue cohorts. Neither gene was associated with TP53, APC, KRAS, NRAS, or BRAF mutations in tissue. However, PIK3CA mutations were strongly associated with ERBB2 mutations in all three cohorts (OR = 3.68, 95% CI = 1.83 to 7.41, P = .001; OR = 2.25, 95% CI = 1.11 to 4.58, P = .02; OR = 2.11, 95% CI = 1.25 to 3.58, P = .004) and ERBB3 mutations in the MDACC cohort (OR = 13.26, 95% CI = 5.27 to 33.33, P < .001). ERBB2 (P = 0.08) and ERBB3 (P = .008) mutations were associated with CMS1 subtype. ERBB2 (hazard ratio [HR] = 1.82, 95% CI = 1.23 to 4.03, P = .009), but not ERBB3 (HR = 0.88, 95% CI = 0.45 to 1.73, P = .73), mutations were associated with worse overall survival. Conclusions: MSI and PIK3CA mutations are associated with ERBB2/ERBB3 mutations. Co-occurring PIK3CA mutations may represent a second hit to oncogenic signaling that needs consideration when targeting ERBB2/ERBB3.
Background: Despite growing therapeutic relevance of ERBB2 amplifications in colorectal cancer (CRC), little is known about ERBB2/ERBB3 mutations. We aimed to characterize these subsets of CRC. Methods: We performed a retrospective analysis of 419 CRCpatients from MD Anderson (MDACC) and 619 patients from the Nurses' Health Study (NHS)/Health Professionals Follow-Up Study (HPFS) with tissue sequencing, clinicopathologic, mutational, and consensus molecular subtype (CMS) profiles of ERBB2/ERBB3 mutant patients. A third cohort of 1623 CRCpatients with ctDNA assays characterized the ctDNA profile of ERBB2 mutants. All statistical tests were two-sided. Results:ERBB2 mutations occurred in 4.1% (95% confidence interval [CI] = 2.4% to 6.4%), 5.8% (95% CI = 4.1% to 8.0%), and 5.1% (95% CI = 4.0% to 6.2%) of MDACC, NHS/HPFS, and ctDNA patients, respectively. ERBB3 mutations occurred in 5.7% (95% CI = 3.7% to 8.4%, 95% CI = 4.0% to 7.8%) of patients in both tissue cohorts. Age, stage, and tumor location were not associated with either mutation. Microsatellite instability (MSI) was associated with ERBB2 (odds ratio [OR] = 5.98, 95% CI = 2.47 to 14.49, P < .001; OR = 5.13, 95% CI = 2.38 to 11.05, P < .001) and ERBB3 mutations (OR = 3.48, 95% CI = 1.51 to 8.02, P = .002; OR = 3.40, 95% CI = 1.05 to 10.96, P = .03) in both tissue cohorts. Neither gene was associated with TP53, APC, KRAS, NRAS, or BRAF mutations in tissue. However, PIK3CA mutations were strongly associated with ERBB2 mutations in all three cohorts (OR = 3.68, 95% CI = 1.83 to 7.41, P = .001; OR = 2.25, 95% CI = 1.11 to 4.58, P = .02; OR = 2.11, 95% CI = 1.25 to 3.58, P = .004) and ERBB3 mutations in the MDACC cohort (OR = 13.26, 95% CI = 5.27 to 33.33, P < .001). ERBB2 (P = 0.08) and ERBB3 (P = .008) mutations were associated with CMS1 subtype. ERBB2 (hazard ratio [HR] = 1.82, 95% CI = 1.23 to 4.03, P = .009), but not ERBB3 (HR = 0.88, 95% CI = 0.45 to 1.73, P = .73), mutations were associated with worse overall survival. Conclusions: MSI and PIK3CA mutations are associated with ERBB2/ERBB3 mutations. Co-occurring PIK3CA mutations may represent a second hit to oncogenic signaling that needs consideration when targeting ERBB2/ERBB3.
Authors: Jong Woo Lee; Young Hwa Soung; Si Hyung Seo; Su Young Kim; Cho Hyun Park; Young Pil Wang; Kyeongmee Park; Suk Woo Nam; Won Sang Park; Sang Ho Kim; Jung Young Lee; Nam Jin Yoo; Sug Hyung Lee Journal: Clin Cancer Res Date: 2006-01-01 Impact factor: 12.531
Authors: Mi Ryoung Choi; Chang Hyeok An; Yeun Jun Chung; Youn Jin Choi; Nam Jin Yoo; Sug Hyung Lee Journal: APMIS Date: 2014-06-07 Impact factor: 3.205
Authors: Funda Meric-Bernstam; Lauren Brusco; Kenna Shaw; Chacha Horombe; Scott Kopetz; Michael A Davies; Mark Routbort; Sarina A Piha-Paul; Filip Janku; Naoto Ueno; David Hong; John De Groot; Vinod Ravi; Yisheng Li; Raja Luthra; Keyur Patel; Russell Broaddus; John Mendelsohn; Gordon B Mills Journal: J Clin Oncol Date: 2015-05-26 Impact factor: 44.544
Authors: Jaclyn F Hechtman; Ahmet Zehir; Rona Yaeger; Lu Wang; Sumit Middha; Tao Zheng; David M Hyman; David Solit; Maria E Arcila; Laetitia Borsu; Jinru Shia; Efsevia Vakiani; Leonard Saltz; Marc Ladanyi Journal: Mol Cancer Res Date: 2015-12-11 Impact factor: 5.852
Authors: Kanwal Raghav; Van Morris; Chad Tang; Pia Morelli; Hesham M Amin; Ken Chen; Ganiraju C Manyam; Bradley Broom; Michael J Overman; Kenna Shaw; Funda Meric-Bernstam; Dipen Maru; David Menter; Lee M Ellis; Cathy Eng; David Hong; Scott Kopetz Journal: Oncotarget Date: 2016-08-23
Authors: David G Menter; Jennifer S Davis; Bradley M Broom; Michael J Overman; Jeffrey Morris; Scott Kopetz Journal: Curr Gastroenterol Rep Date: 2019-01-30
Authors: Keisuke Kosumi; Tsuyoshi Hamada; Hideo Koh; Jennifer Borowsky; Susan Bullman; Tyler S Twombly; Daniel Nevo; Yohei Masugi; Li Liu; Annacarolina da Silva; Yang Chen; Chunxia Du; Mancang Gu; Chenxi Li; Wanwan Li; Hongli Liu; Yan Shi; Kosuke Mima; Mingyang Song; Katsuhiko Nosho; Jonathan A Nowak; Reiko Nishihara; Hideo Baba; Xuehong Zhang; Kana Wu; Molin Wang; Curtis Huttenhower; Wendy S Garrett; Matthew L Meyerson; Jochen K Lennerz; Marios Giannakis; Andrew T Chan; Jeffrey A Meyerhardt; Charles S Fuchs; Shuji Ogino Journal: Am J Pathol Date: 2018-09-20 Impact factor: 4.307
Authors: Jonathan M Loree; Yucai Wang; Muddassir A Syed; Alexey V Sorokin; Oluwadara Coker; Joanne Xiu; Benjamin A Weinberg; Ari M Vanderwalde; Anteneh Tesfaye; Victoria M Raymond; Benjamin Miron; Gabi Tarcic; Ori Zelichov; Russell R Broaddus; Patrick Kwok Shing Ng; Kang Jin Jeong; Yiu Huen Tsang; Gordon B Mills; Michael J Overman; Axel Grothey; John L Marshall; Scott Kopetz Journal: Clin Cancer Res Date: 2021-06-11 Impact factor: 12.531